Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://link.springer.com/article/10.1007/s00262-006-0194-y, but it redirected us to https://link.springer.com/article/10.1007/s00262-006-0194-y. The analysis below is for the second page.

Title[redir]:
CD4 regulatory T cells in human cancer pathogenesis | Cancer Immunology, Immunotherapy
Description:
Over the past decade, there has been an accelerated understanding of immune regulatory mechanisms. Peripheral immune regulation is linked to a collection of specialized regulatory cells of the CD4+ T cell lineage (i.e., CD4+ Tregs). This collection consists of Tregs that are either thymically derived (i.e., natural) or peripherally induced. Tregs are important for controlling potentially autoreactive immune effectors and immunity to foreign organisms and molecules. Their importance in maintaining immune homeostasis and the overall health of an organism is clear. However, Tregs may also be involved in the pathogenesis of malignancies as now compelling evidence shows that tumors induce or recruit CD4+ Tregs to block immune priming and antitumor effectors. Efforts are underway to develop approaches that specifically inhibit the function of tumor-associated Tregs which could lead to an increased capability of the body’s immune system to respond to tumors but without off-target immune-related pathologies (i.e., autoimmune disease). In this review, the biology of human CD4+ Tregs is discussed along with their involvement in malignancies and emerging strategies to block their function.

Matching Content Categories {📚}

  • Science
  • Education
  • Health & Fitness

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We can't tell how the site generates income.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Doi.org might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

google, scholar, pubmed, cas, cells, regulatory, cancer, immunol, patients, human, cdcd, immunity, med, cell, immune, res, foxp, exp, tumor, clin, blood, peripheral, nat, rev, breast, ovarian, carcinoma, function, article, tregs, lymphocytes, immunotherapy, disis, knutson, induction, melanoma, syndrome, tumors, tumour, ziegler, role, romagnani, sakaguchi, interleukin, immunother, factor, ipex, protein, tcell, responses,

Topics {✒️}

tumor-infiltrating foxp3+cd25+cd4+ regulatory pre-existing t-cell immunity t-cell-mediated antitumor immunity forkhead/winged-helix protein cd4+cd25high regulatory t-cells tumor-draining lymph nodes month download article/chapter tgf-beta-producing regulatory target immune-related pathologies lasting immune-mediated rejection tetramer+ p53 peptide-specific cyclophosphamide-facilitated adoptive immunotherapy inducing t-cell tolerance her2/neu-derived peptide agonistic anti-gitr mab vaccine-mediated antitumor immunity infiltrating cd4+ t-cells human cd4+cd25high regulatory stimulated human cd4+cd25 il-10-producing cd4+cd25+ foxp3 expressing cd4+cd25 lymphocyte-recognized antigen system late-stage ovarian cancer class ii tetramers cd4+cd25+ regulatory thymocytes ovarian cancer-specific cytotoxic tgf-beta 1 plays shape tumour immunogenicity interleukin-2 receptor alpha privacy choices/manage cookies basiliximab versus placebo article cancer immunology sentinel lymph nodes tumour lymphocytic infiltrate existent t-cell renal allograft recipients independent prognostic factor cell-mediated immunity immune suppressive activity immunologically mediated regression full article pdf t-cell responses malignant pleural effusion recombinant immunotoxin lmb-2 acute cellular rejection quantify antigen-specific infiltrating ductal carcinoma x-linked syndrome renal cell carcinoma poorly immunogenic melanoma

Questions {❓}

  • Moller G (1988) Do suppressor T cells exist?
  • Tipping the balance in autoimmunity: are regulatory t cells the cause, the cure, or both?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:CD4 regulatory T cells in human cancer pathogenesis
         description:Over the past decade, there has been an accelerated understanding of immune regulatory mechanisms. Peripheral immune regulation is linked to a collection of specialized regulatory cells of the CD4+ T cell lineage (i.e., CD4+ Tregs). This collection consists of Tregs that are either thymically derived (i.e., natural) or peripherally induced. Tregs are important for controlling potentially autoreactive immune effectors and immunity to foreign organisms and molecules. Their importance in maintaining immune homeostasis and the overall health of an organism is clear. However, Tregs may also be involved in the pathogenesis of malignancies as now compelling evidence shows that tumors induce or recruit CD4+ Tregs to block immune priming and antitumor effectors. Efforts are underway to develop approaches that specifically inhibit the function of tumor-associated Tregs which could lead to an increased capability of the body’s immune system to respond to tumors but without off-target immune-related pathologies (i.e., autoimmune disease). In this review, the biology of human CD4+ Tregs is discussed along with their involvement in malignancies and emerging strategies to block their function.
         datePublished:2006-07-04T00:00:00Z
         dateModified:2006-07-04T00:00:00Z
         pageStart:271
         pageEnd:285
         sameAs:https://doi.org/10.1007/s00262-006-0194-y
         keywords:
            Tregs
            IPEX
            Foxp3
            Ontak
            Toxin
            CD25
            Oncology
            Immunology
            Cancer Research
         image:
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:56
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Keith L. Knutson
               affiliation:
                     name:Mayo Clinic College of Medicine
                     address:
                        name:Department of Immunology, Mayo Clinic College of Medicine, Rochester, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Mary L. Disis
               affiliation:
                     name:Center for Translational Medicine in Women’s Health
                     address:
                        name:Tumor Vaccine Group, Center for Translational Medicine in Women’s Health, Seattle, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lupe G. Salazar
               affiliation:
                     name:Center for Translational Medicine in Women’s Health
                     address:
                        name:Tumor Vaccine Group, Center for Translational Medicine in Women’s Health, Seattle, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:CD4 regulatory T cells in human cancer pathogenesis
      description:Over the past decade, there has been an accelerated understanding of immune regulatory mechanisms. Peripheral immune regulation is linked to a collection of specialized regulatory cells of the CD4+ T cell lineage (i.e., CD4+ Tregs). This collection consists of Tregs that are either thymically derived (i.e., natural) or peripherally induced. Tregs are important for controlling potentially autoreactive immune effectors and immunity to foreign organisms and molecules. Their importance in maintaining immune homeostasis and the overall health of an organism is clear. However, Tregs may also be involved in the pathogenesis of malignancies as now compelling evidence shows that tumors induce or recruit CD4+ Tregs to block immune priming and antitumor effectors. Efforts are underway to develop approaches that specifically inhibit the function of tumor-associated Tregs which could lead to an increased capability of the body’s immune system to respond to tumors but without off-target immune-related pathologies (i.e., autoimmune disease). In this review, the biology of human CD4+ Tregs is discussed along with their involvement in malignancies and emerging strategies to block their function.
      datePublished:2006-07-04T00:00:00Z
      dateModified:2006-07-04T00:00:00Z
      pageStart:271
      pageEnd:285
      sameAs:https://doi.org/10.1007/s00262-006-0194-y
      keywords:
         Tregs
         IPEX
         Foxp3
         Ontak
         Toxin
         CD25
         Oncology
         Immunology
         Cancer Research
      image:
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:56
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Keith L. Knutson
            affiliation:
                  name:Mayo Clinic College of Medicine
                  address:
                     name:Department of Immunology, Mayo Clinic College of Medicine, Rochester, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Mary L. Disis
            affiliation:
                  name:Center for Translational Medicine in Women’s Health
                  address:
                     name:Tumor Vaccine Group, Center for Translational Medicine in Women’s Health, Seattle, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lupe G. Salazar
            affiliation:
                  name:Center for Translational Medicine in Women’s Health
                  address:
                     name:Tumor Vaccine Group, Center for Translational Medicine in Women’s Health, Seattle, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:56
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Mayo Clinic College of Medicine
      address:
         name:Department of Immunology, Mayo Clinic College of Medicine, Rochester, USA
         type:PostalAddress
      name:Center for Translational Medicine in Women’s Health
      address:
         name:Tumor Vaccine Group, Center for Translational Medicine in Women’s Health, Seattle, USA
         type:PostalAddress
      name:Center for Translational Medicine in Women’s Health
      address:
         name:Tumor Vaccine Group, Center for Translational Medicine in Women’s Health, Seattle, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Keith L. Knutson
      affiliation:
            name:Mayo Clinic College of Medicine
            address:
               name:Department of Immunology, Mayo Clinic College of Medicine, Rochester, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Mary L. Disis
      affiliation:
            name:Center for Translational Medicine in Women’s Health
            address:
               name:Tumor Vaccine Group, Center for Translational Medicine in Women’s Health, Seattle, USA
               type:PostalAddress
            type:Organization
      name:Lupe G. Salazar
      affiliation:
            name:Center for Translational Medicine in Women’s Health
            address:
               name:Tumor Vaccine Group, Center for Translational Medicine in Women’s Health, Seattle, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Immunology, Mayo Clinic College of Medicine, Rochester, USA
      name:Tumor Vaccine Group, Center for Translational Medicine in Women’s Health, Seattle, USA
      name:Tumor Vaccine Group, Center for Translational Medicine in Women’s Health, Seattle, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(440)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Particles.js
  • Prism.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Crossref

4.65s.